Oramed’s ORMD-0801 Fails in Type 2 Diabetes Study

Oramed Pharmaceuticals’ investigational oral drug ORMD-0801 did not meet the primary endpoint of improving glycemic control in a phase 3 clinical trial evaluating the drug in type 2 diabetes.

The drug also did not meet the study’s second endpoint of achieving mean change of the fasting plasma glucose from baseline.

Because of the disappointing results, the company plans on discontinuing development of ORMD-0801 for type 2 diabetes.